- Activity pressure is positive on the latest completed week.
- Volume is elevated versus the 13-week average, confirming attention.
KRSNAA
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Krsnaa Diagnostics Limited · Healthcare · Diagnostics & Research
Latest close
560.8 INR
6.3%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -5.6% below the Trend Line and sits at 12.1% of its 52-week range. The latest completed week returned 6.3%, after a 0.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 60/100.
Setup score
33
out of 100
Latest Close
560.8 INR
7 Aug 2026
1W Return
6.3%
latest completed week
4W Return
0.8%
short-term follow-through
12W Return
-4.0%
quarterly tape
Trend Breadth
30.8%
16 of 52 weeks active
Volume Ratio
2.1x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 37.69% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
6.3%
Latest completed week; four-week move 0.8%.
Indicator stack
17/53
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 37.69%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
60/100
22 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -5.6% below the Trend Line and sits at 12.1% of its 52-week range. The latest completed week returned 6.3%, after a 0.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 2.1x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0312-week average 0.02
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.03Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 0.8% over four weeks, -4.0% over 12 weeks, and -33.7% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year16
Trend breadth30.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.08Latest activity-pressure read.
Pressure change16.1%Four-week change in activity pressure.
Leadership-15.81Latest relative-leadership reading.
RS change11.7%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 94%
Model confidence 88%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength46/100Blend of value, momentum, and quality. Underlying universe rank 55; rank 1 is best.
Value75/100Relative valuation strength. Underlying universe rank 26; rank 1 is best.
Quality36/100Profitability and accounting quality. Underlying universe rank 65; rank 1 is best.
Momentum8/100Medium-term price momentum. Underlying universe rank 93; rank 1 is best.
Growth64/100Revenue and earnings growth. Underlying universe rank 37; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework48/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 17.9x Price divided by trailing earnings.
- Price / sales
- 2.4x Market value relative to trailing revenue.
- EV / EBITDA
- 9.1x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -3.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 68.8% Gross profit retained from each unit of revenue.
- Operating margin
- 15.7% Operating profit retained from revenue.
- Free-cash-flow margin
- -9.9% Free cash flow generated from revenue.
- Return on invested capital
- 6.1% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 7.8% Latest one-year revenue growth.
- EPS growth
- 30.1% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.5% Cash dividends relative to market value.
- Buyback yield
- -0.2% Net share repurchases relative to market value.
- Shareholder yield
- 0.3% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment60/100
Weighted news tone is positive across 22 relevant articles.
2 positive · 18 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-37.3%Distance below the 52-week high.
13-week volatility3.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher9 of 2617 weeks finished lower.
Best week+8.2%Week of 10 Apr.
Worst week-6.9%Week of 27 Mar.
Latest week+6.3%Week of 7 Aug.
Shape of recent returns
Strong gains4
Modest gains5
Flat weeks0
Modest losses15
Sharp losses2
Recent vol3.0%13-week weekly-return volatility.
Base vol4.1%52-week weekly-return volatility.
Up/down split19/33Count of positive and negative weeks in the 52-week window.
Average skew3.6% / -3.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank- / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Diagnostics & Research
4-week rank5 / 9
Group average4.7%
Trend breadth66.7%
Trend66.7%active weekly trend signals
MD77.8%positive activity pressure
RS66.7%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape29/100
Trend, activity pressure, participation, and risk combine to a 29/100 tape read.
Indicator analysis18/100Latest 12-week confirmation: trend 0/12, activity pressure 5/12, relative leadership 0/12.
Activity pressure 0.03; No reversal markers Next-Week ExpectancyNegative 37.69%Next-week expectancy is negative with a 37.69% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors41/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 80; Small Cap Core rank 28 SVQF48/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 824.0 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment60/100Weighted news tone is positive across 22 relevant articles.
Adaptive Biotechnologies (ADPT) Stock Analysis: Revenue Growth Signals Strong Potential In Diagnostics & Research Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 560.8 INR | 6.3% | 594.2 INR | 705.5 INR | 0.08 | -15.81 | 501.3K | Off |
| 31 Jul 2026 | 527.5 INR | -3.2% | 599.9 INR | 705.1 INR | -0.12 | -20.89 | 239.3K | Off |
| 24 Jul 2026 | 544.8 INR | 0.9% | 606.8 INR | 705.1 INR | 0.05 | -16.88 | 280.3K | Off |
| 17 Jul 2026 | 540.0 INR | -3.0% | 613.0 INR | 704.7 INR | 0.07 | -20.16 | 190.7K | Off |
| 10 Jul 2026 | 556.7 INR | -1.1% | 619.0 INR | 704.1 INR | 0.07 | -17.92 | 222.3K | Off |
| 3 Jul 2026 | 562.8 INR | 4.6% | 624.9 INR | 704.0 INR | -0.11 | -17.74 | 62.4K | Off |
| 26 Jun 2026 | 538.2 INR | 1.3% | 631.2 INR | 704.1 INR | -0.26 | -20.88 | 0 | Off |
| 19 Jun 2026 | 531.3 INR | -0.6% | 640.3 INR | 704.3 INR | -0.15 | -22.02 | 55.9K | Off |
| 12 Jun 2026 | 534.3 INR | -3.2% | 649.8 INR | 704.5 INR | -0.13 | -20.60 | 112.1K | Off |
| 5 Jun 2026 | 551.9 INR | 0.4% | 658.9 INR | 704.8 INR | -0.08 | -17.35 | 43.9K | Off |
| 29 May 2026 | 549.5 INR | -2.3% | 664.6 INR | 704.8 INR | 0.05 | -18.53 | 947.6K | Off |
| 22 May 2026 | 562.5 INR | -3.7% | 672.2 INR | 704.9 INR | -0.20 | -17.33 | 154.0K | Off |
| 15 May 2026 | 584.4 INR | -2.5% | 680.2 INR | 704.5 INR | -0.31 | -13.95 | 291.2K | Off |
| 8 May 2026 | 599.5 INR | 1.8% | 686.7 INR | 704.3 INR | -0.53 | -13.74 | 646.3K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.